Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer

References

• Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics 2007. CA Cancer J. Clin.57(1), 43–66 (2007).
   PubMed Web of Science ®Google Scholar
• Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol.10(6), 896–903 (1992).
   PubMed Web of Science ®Google Scholar
• Meta-analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J. Clin. Oncol.16(1), 301–308 (1998).
   PubMed Web of Science ®Google Scholar
• Thirion P, Michiels S, Pignon JP et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol.22(18), 3766–3775 (2004).
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet355(9209), 1041–1047 (2000).
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.22(1), 23–30 (2004).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.18(16), 2938–2947 (2000).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22(2), 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Cox JV, Blanke C et al.Irinotecan plus fluorouracil andleucovorin for metastatic colorectalcancer. Irinotecan Study Group.N. Engl. J. Med.343(13), 905–914 (2000).
   PubMed Web of Science ®Google Scholar
• Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improveswith the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatinin the course of treatment. J. Clin. Oncol.22(7), 1209–1214 (2004).
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of thevascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol.23(5), 1011–1027 (2005).
   PubMed Web of Science ®Google Scholar
• Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol.21(14), 2787–2799 (2003).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Schulz J, McCleod M et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized Phase II trial. J. Clin. Oncol.23(16), 3697–3705 (2005).
   PubMed Web of Science ®Google Scholar
• Giantonio BJ, Catalano PJ, Meropol NJ et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol.25(12), 1539–1544 (2007).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Wilke H, Glynne-Jones R, Thaler J et al. MABEL – a large multinational study of cetuximab plus irinotecan in metastatic colorectal cancer progressing on irinotecan. J. Clin. Oncol.25(Suppl. 18), 3549 (2006).
   Google Scholar
• Jonker DJ, O’Callaghan CJ, Karapetis CS et al. Cetuximab for the treatment of colorectal cancer. N. Engl. J. Med.357(20), 2040–2048 (2007).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Nowacki M, Lang I et al. Randomized phase III study ofirinotecan and 5-FU/FA with orwithout cetuximab in the first-line treatment of patients with metastatic colorectal cancer: the CRYSTAL trial.J. Clin. Oncol.25(Suppl. 18), 4000 (2007).
   Google Scholar
• Bokemeyer C, Bondarenko I, Makhson A et al. Cetuximab plus 5-FU/FA/oxaliplatin (FOLFOX-4) versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer: OPUS, a randomized Phase II study. J. Clin. Oncol.25(Suppl. 18) 4035 (2007).
   Google Scholar
• Van Cutsem E, Peeters M, Siena S et al. Open-label Phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol.25(13), 1658–1664 (2007).
   PubMed Web of Science ®Google Scholar
• Saltz LB, Rosen LS, Marshall JL et al. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. J. Clin. Oncol.25(30), 4793–4799 (2007).
   PubMed Web of Science ®Google Scholar
• Arteaga CL. The epidermal growthfactor receptor: from mutant oncogenein nonhuman cancers to therapeutictarget in human neoplasia. J. Clin.Oncol.19(Suppl. 18), S32–S40 (2001).
   PubMed Web of Science ®Google Scholar
• Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N. Engl. J. Med.353(2), 172–187 (2005).
   PubMed Web of Science ®Google Scholar
• Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur. J.Cancer37(Suppl. 4) S9–S15 (2001).
   PubMedGoogle Scholar
• Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res.1(11), 1311–1318 (1995).
   PubMed Web of Science ®Google Scholar
• Kimura H, Sakai K, Arao T,Shimoyama T, Tamura T, Nishio K. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor. Cancer Sci.98(8), 1275–1280 (2007).
   PubMed Web of Science ®Google Scholar
• Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin. Cancer Res.8(5), 994–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann. Oncol.14(Suppl. 2) ii13–ii16 (2003).
   PubMed Web of Science ®Google Scholar
• Raymond E, Faivre S, Woynarowski JM, Chaney SG. Oxaliplatin: mechanism of action and antineoplastic activity. Semin. Oncol.25(2 Suppl. 5), 4–12 (1998).
   PubMed Web of Science ®Google Scholar
• Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer – a GERCOR study. J. Clin. Oncol.24(3), 394–400 (2006).
   PubMed Web of Science ®Google Scholar
• Cassidy J, Misset JL. Oxaliplatin-related side effects: characteristics and management. Semin. Oncol.29(5 Suppl. 15), 11–20 (2002).
   PubMed Web of Science ®Google Scholar
• Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin. Oncol.30(4 Suppl. 15), 5–13 (2003).
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med.350(23), 2343–2351 (2004).
   PubMed Web of Science ®Google Scholar
• de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J. Clin. Oncol.25(Suppl. 18) 4007 (2007).
   Web of Science ®Google Scholar
• Nordlinger B, Sorbye H, Collette L et al. Final results of the EORTC intergroup randomized phase III study 40983 evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J. Clin. Oncol.25(Suppl. 18), LBA5 (2007).
   Web of Science ®Google Scholar
• Prewett M, Bassi R, Carrick F et al. Cetuximab (Erbitux) enhances clinical efficacy of oxaliplatin in human colon carcinoma xenografts and reverses oxaliplatin resistance. Presented at: 2005 AACR-NCI-EORTC Annual Meeting. Philadelphia, PA, USA, 14–18 November, 2005.
   Google Scholar
• Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res6(6), 2166–2174 (2000).
   PubMed Web of Science ®Google Scholar
• Dittmann K, Mayer C, Fehrenbacher B et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J. Biol. Chem.280(35), 31182–31189 (2005).
   PubMed Web of Science ®Google Scholar
• Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat. Rev. Mol. Cell Biol.2(2), 127–137 (2001).
   PubMed Web of Science ®Google Scholar
• Tabernero J, Van Cutsem E, Diaz-Rubio E et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol.25(33), 5225–5232 (2007).
   PubMed Web of Science ®Google Scholar
• Colucci G, Giuliani F, Mattioli R et al. FOLFOX-4 plus cetuximab in untreated patients with advanced colorectal cancer. A Phase II study of the Gruppo Oncologico dell´Italia Meridionale (prot. GOIM 2402). J. Clin. Oncol.24(Suppl. 18), 3559 (2006).
   Google Scholar
• Dakhil S, Cosgriff T, Headley D, Boccia R, Badarinath S. Cetuximab plus FOLFOX6 as first line therapy for metastatic colorectal cancer (an International Oncology Network study, I-03–002). J. Clin. Oncol.24(Suppl. 18) 3557 (2006).
   Google Scholar
• Dittrich C, Hoehler T, Lordick F et al. A Phase I/II study of cetuximab in combination with 5-fluorouracil/folinic acid plus weekly oxaliplatin (FUFOX) in the first-line treatment of patients with metastatic colorectal cancer expressing epidermal growth factor receptor (EGFR). Preliminary results. Ann Oncol.17(24 Suppl.), O–019 (2006).
   Google Scholar
• Borner M, Mingrone W, Koeberle D et al. The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK). J. Clin. Oncol.24(Suppl. 18) 3551 (2006).
   Google Scholar
• Heinemann V, Fischer von Weikersthal L, Moosmann N et al. Cetuximab plus capecitabine plus irinotecan versus cetuximab plus capecitabine plus oxaliplatin as first line therapy for patients with metastatic colorectal cancer: preliminary results of a randomized Phase II trial of the AIO study group.J. Clin. Oncol.24(Suppl. 18) 3550 (2006).
   Google Scholar
• Venook A, Niedzwiecki D, Hollis D et al. Phase III study of irinotecan/5-FU/LV (FOLFIRI) or oxaliplatin/5-FU/LV (FOLFOX) +/- cetuximab (C225) for patients (pts) with untreated metastatic adeno carcinoma of the colon or rectum (mCRC): CALGB 80203 preliminary results. J. Clin. Oncol.24(Suppl. 18) 3509 (2006).
   PubMed Web of Science ®Google Scholar
• Folprecht G, Grothey A, Alberts S, Raab HR, Kohne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann. Oncol.16(8), 1311–1319 (2005).
   PubMed Web of Science ®Google Scholar
• Polikoff J, Mitchell E, Badarinath S et al. Erbitux (cetuximab) plus FOLFOX for colorectal cancer (EXPLORE): preliminary efficacy analysis of a randomized Phase III-trial. J. Clin. Oncol.23(Suppl.), 3574 (2005).
   Google Scholar
• Portier G, Elias D, Bouche O et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J. Clin. Oncol.24(31), 4976–4982 (2006).
   PubMed Web of Science ®Google Scholar
• Hecht JR, Chidiac T, Mitchell E et al. An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab for metastatic colorectal cancer. Presented at: World Congress on Gastrointestinal Cancer (WCGI). Barcelona, Spain, 27–30 June, 2007.
   Google Scholar
• Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol.23(22), 5235–5246 (2005).
   PubMed Web of Science ®Google Scholar
• Segaert S, Tabernero J, Chosidow O et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J. Dtsch Dermatol. Ges.3(8), 599–606 (2005).
   PubMedGoogle Scholar
• Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann. Oncol.16(9), 1425–1433 (2005).
   PubMed Web of Science ®Google Scholar
• Saltz L, Kies MS, Abbruzzese JL, Azarnia N, Needle MN. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc. Am. Soc. Clin. Oncol.22, 817 (2003).
   Google Scholar
• Saltz LB, Meropol NJ, Loehrer PJ Sr. Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol.22(7), 1201–1208(2004).
   PubMed Web of Science ®Google Scholar
• Lievre A, Bachet JB, Le Corre D et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res.66(8), 3992–3995 (2006).
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol.25(22), 3230–3237 (2007).
   PubMed Web of Science ®Google Scholar